1-4 of 4
Yousef Zakharia
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma

Sylvia M. Lee, Omid Hamid, Robert Jotte, Yousef Zakharia, Theresa Medina, Amanda Gillespie-Twardy, Inderjit Mehmi, Sunandana Chandra, Graham Watson, Patrick Ward, Marya Chaney, Hailing Lu, Jason Berndt, Brian P. O’Connor, Kapil Rathi, Eeman Shaikh, Charles Lance Cowey
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF12.
https://doi.org/10.1158/1078-0432.CCR-24-1478
Published: 24 January 2025
View article titled, Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma
Open the PDF for Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma in another window
Includes: Supplementary data
Journal Articles

Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial

Espen B. Ellingsen, Steven O'Day, Artur Mezheyeuski, Agnieszka Gromadka, Trevor Clancy, Timothy S. Kristedja, Mohammed Milhem, Yousef Zakharia
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (16): 3026–3036.
https://doi.org/10.1158/1078-0432.CCR-23-0416
Published: 15 August 2023
View article titled, Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial
Open the PDF for Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial in another window
Includes: Supplementary data
Journal Articles

SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma

Lisa A. Kottschade, Gregory Russell Pond, Anthony J. Olszanski, Yousef Zakharia, Evidio Domingo-Musibay, Ralph J. Hauke, Brendan D. Curti, Sarah Schober, Mohammed M. Milhem, Matthew Stephen Block, Tina Hieken, Robert R. McWilliams
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (12): 2220–2225.
https://doi.org/10.1158/1078-0432.CCR-22-3207
Published: 13 June 2023
View article titled, SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma
Open the PDF for SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma in another window
Includes: Supplementary data
Journal Articles

Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial

Chung-Han Lee, Robert Motzer, Hamid Emamekhoo, Marc Matrana, Ivor Percent, James J. Hsieh, Arif Hussain, Ulka Vaishampayan, Sandy Liu, Steven McCune, Vijay Patel, Montaser Shaheen, Johanna Bendell, Alice C. Fan, Benjamin A. Gartrell, Oscar B. Goodman, Jr, Petros G. Nikolinakos, Arash Rezazadeh Kalebasty, Yousef Zakharia, Zhentao Zhang, Hema Parmar, Lalith Akella, Keith Orford, Nizar M. Tannir
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (15): 3248–3255.
https://doi.org/10.1158/1078-0432.CCR-22-0061
Published: 02 August 2022
View article titled, Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial
Open the PDF for Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial in another window
Includes: Supplementary data